Compare Novartis AG (NVS) vs Open Text Corporation (OTEX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Open Text Corporation — how do they compare? Novartis AG trades at $142.04 (market cap $274.00B), while Open Text Corporation trades at $23.25 (market cap $5.62B). The key difference: Novartis AG is far larger — about 48.8× Open Text Corporation's market cap, and Open Text Corporation pays the higher dividend (4.84%). Which is the better fit depends on your goals — on Pluang, investors hold Novartis AG for 82 Days and Open Text Corporation for 23 Days on average.
| NVS | OTEX | |
|---|---|---|
Market Cap | $274.00B | $5.62B |
Volume | 1,852,137 | 1,217,244 |
Sector | Health | Technology |
52-Week High | $168.62 | $39.69 |
52-Week Low | $121.80 | $20.01 |
Typical Hold Time | 82 Days | 23 Days |
Enterprise Value | $315.32B | $10.64B |
Dividend Yield | 3.31% | 4.84% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $143.11, up 1.65% with mixed technical signals showing neutral momentum. The company maintains strong profitability with 22.5% net margins and recently announced a $7.8B licensing deal with China's Abogen. Recent earnings show two beats and one miss in the last three quarters, with Q3 2026 results pending. The stock trades below the consensus price target of $146, suggesting modest upside potential from current levels.
Novartis presents a balanced investment case with strong cash flow generation and profitability offset by recent clinical setbacks and M&A scrutiny. The $7.8B Abogen partnership expands the autoimmune pipeline, but investors face risks from patent cliffs and drug development failures. Analyst consensus leans cautious with 68% hold ratings, reflecting uncertainty around pipeline execution amid ongoing strategic repositioning.
OpenText (OTEX) trades at $23.14, up 1.89% with a bullish technical signal despite mixed moving averages. The company shows strong fundamentals with a P/E of 8.97 and consistent earnings beats, including Q2 2026 EPS of $1.23 beating expectations by 20.6%. Recent debt refinancing activities and a strategic AI partnership with Cohere highlight management's focus on growth and financial flexibility.
OTEX presents a compelling value opportunity with discounted valuation multiples and improving cloud momentum, though elevated debt levels and competitive pressures remain key risks. Analyst consensus targets $28.30 (22% upside) with 42% buy ratings, suggesting cautious optimism for the software company's transformation efforts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Open Text Corporation
Open Text Corporation is a global leader in Enterprise Information Management (EIM) software and solutions. The company provides a comprehensive platform that helps organizations manage, secure, and leverage their unstructured digital content, including documents, emails, and media files. OTEX's offerings span content management, business process management, customer experience management, and security, serving large enterprises across various industries worldwide.
Read more on OTEX →
